Your eight-year-old daughter is sitting on your front steps right now in the freezing cold, my neighbor Brenda whispered over the phone at 12:14 AM. "Her clothes are covered in wet blood, Mark. S...
It was 10:30 PM. The federal grant submission deadline for Protocol 409 was midnight, less than ninety minutes away. The city outside was a blur of tail lights and distant sirens as I drove back to St. Jude.
Using the administrative keycard Chloe had secretly left on my passenger seat, a small plastic rectangle with a magnetic strip, I entered the subterranean records basement of St. Jude Memorial Hospital. The basement was a quiet labyrinth of concrete corridors, cold air pipes dripping condensation onto the floor, and floor-to-ceiling metal shelving holding decades of dusty paper medical files. The air was thick with the smell of old paper and ozone.
My heart hammered against my ribs as my footsteps echoed down Storage Aisle 14. Fluorescent lights hummed overhead, casting a sickly yellow glow on the rows of drab gray boxes. I reached the section marked *2023 – Clinical Trial Compliance – Ward 4B.* It was exactly where Chloe had indicated it would be.
I pulled down the box labeled *Protocol 409-A Adult Trials – Patient Autopsy Reports.* The cardboard was brittle, a fine layer of dust coating my fingers.
I opened the folder for Sarah Gable. Inside was the original physical blood work report signed by the chief pathologist seven months ago—a report that had never been uploaded to the electronic patient chart I received after her death. The official hospital report had simply stated “acute liver failure due to aggressive leukemia.”
The paper showed Sarah’s liver failure was directly triggered by a severe toxic interaction with Compound PX-409. The dosage listed on the report was dangerously high, administered under Evelyn’s direct administrative order three days before she died. Not “late-stage leukemia complications,” but a lethal overdose.
Attached to the back of the autopsy sheet was a handwritten memo on Evelyn’s personal trustee stationery, scrawled in her precise, angular script:
*Do not release physical toxicology panel to surviving spouse. Hold baseline pending pediatric Phase B enrollment. Urgent.*
She needed Maya’s pediatric baseline data. She needed it to retroactively prove to the grant board that the toxic reaction in Sarah was an isolated genetic outlier, a rare individual response, rather than a fatal flaw in the drug itself. The two point five million dollar grant, and her career, depended on it. Evelyn’s administrative position and pension depended on hiding this link from federal regulators before the audit deadline that very weekend.
I pulled out my phone and took high-resolution photographs of every single page, every line, every signature. The flash lit up the dusty archive, each click a silent accusation.
More Stories
+ There are no comments
Add yours